title: Population pharmacokinetic analysis of ceftobiprole for treatment of complicated skin and skin structure infections.
abstract: Population pharmacokinetic analysis demonstrated that renal function, as assessed by creatinine clearance (CL(CR)), was the patient characteristic that had a clinically relevant impact on ceftobiprole pharmacodynamics. Dosing adjustments based on CL(CR) for subjects with renal impairment should provide ceftobiprole exposure similar to that in patients with normal renal function.
authors.affiliation: Johnson & Johnson Pharmaceutical Research & Development, LLC, South Raritan, NJ 08869, USA. HKimko@its.jnj.com
authors.forename: Holly
authors.initials: H
authors.lastname: Kimko
authors.forename: Bindu
authors.initials: B
authors.lastname: Murthy
authors.forename: Xu
authors.initials: X
authors.lastname: Xu
authors.forename: Partha
authors.initials: P
authors.lastname: Nandy
authors.forename: Richard
authors.initials: R
authors.lastname: Strauss
authors.forename: Gary J
authors.initials: GJ
authors.lastname: Noel
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D016022:Case-Control Studies; D002511:Cephalosporins / Q000008:administration & dosage / Q000493:pharmacokinetics*; D017326:Clinical Trials, Phase III as Topic; D003198:Computer Simulation; D003404:Creatinine / Q000493:pharmacokinetics; D006801:Humans; D007262:Infusions, Intravenous; D007677:Kidney Function Tests; D008297:Male; D008657:Metabolic Clearance Rate; D008826:Microbial Sensitivity Tests; D008954:Models, Biological; D011153:Population / Q000235:genetics; D012874:Skin Diseases, Infectious / Q000188:drug therapy*; D012984:Software
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; C443755:ceftobiprole; D003404:Creatinine